Author index

A

Agui, T., see Kebabian, J. W.
Allen, T. M., see Cook, D. A.
Andersson, R. G. G., Grundstrom, N. and Lindgren, B. R., α-Adrenoceptors and asthma 177
Andrews, P., Functional groups, drug-receptor interactions and drug design 148
Anholt, R. R. H., Mitochondrial benzodiazepine receptors as potential modulators of intermediary metabolism 506
Ariens, E. J., Chirality in bioactive agents and its pitfalls 200
Armour, C. L., see Black, J. L.
Arrang, J-M., see Schwartz, J-C.

B

Baksaas, I and Lunde, P. K. M., National drug policies, need for drug utilization studies 331
Ball, S. G., see Vanhoutte, P. M.
Baranyi-Furlong, B. L., see Goodman, J. I.
Barlow, R. B., A memorial to Heinz Schild: can 'hormone' receptors be classified 79
Bast, A., Is formation of reactive oxygen by cytochrome P-450 perilous and predictable? 266
Bast, A., see Stroes, J. W.
Batty, I., see Nahorski, S. R.
Beart, P. M., see Manallack, D. T.
Beck, T. and Bielenberg, G. W., Pharmacological intervention of cerebral ischemia 425
Benovic, J. L., see Lefkowitz, R. J.
Berdeaux, A., see Vanhoutte, P. M.
Berg. D., Büchel, K-H., Plempel, M., Regal, E., Antimycotic sterol biosynthesis inhibitors 233
Bevan, J. A., Cutler, S. G. and Schmidek, H. H., Chronic cerebral vasospasm is not due to active muscle contraction 345
Bianchetti, A., see Manara, L.
Bielenberg, G. W., see Beck, T.
Biziere, K., see Wermuth, C. G.
Black, J. L. and Armour, C. L., α-Adrenoceptor function in asthma 303
Blaha, C. D., see Phillips, A. G.
Blumberg, J. B., Clinical significance of drug-nutrient interactions 33
Bolt, G. R., see Saxena, P. R.
Boyer, J. L., see Garcia-Sainz, J. A.
Brantl, V. and Neubert, K., Opioid peptides derived from food proteins 6
Braquet, P., see Godfroid, J. J.
Braquet, P. and Godfroid. J. J., PAF-acether specific binding sites: 2. Design of specific antagonists 397
Büchel, K-H., see Berg, D.
Buck, S. H. and Burcher, E., The tachykinins: a family of peptides with a brood of 'receptors' 65
Buck, S. H. and Burcher, E., Buck and Bercher reply 302
Buck, S. H. and Burcher, E., Neurokinin binding site nomenclature-definition 437
Burcher, E., see Buck, S. H.
Burks, T. F., see Porreca, F.
Burks, T. F., Undergraduate education in pharmacology and toxicology in the USA 207

C

Caron, M. G., see Lefkowitz, R. J.
Cerami, A. and Crabbe, M. J. C., Recent advances in ocular cataract research 271
Chambers, P. L., New experimental approaches to behavioural toxicology 471
Chaudhury, R. R., Folklore herbal contraceptives and remedies 121
Cheng, J. B., LTC_4 'receptor': its demonstration using airway and non-airway tissues 477
Church, M. K. and Holgate, S. T., Adenosine and asthma 49
Clarke, S. R., see Taylor, G. W.
Claudio, T., Recombinant DNA technology in the study of ion channels 308
Cohen, M. L., see Vanhoutte, P. M.
Colhoun, E. H. and Rylett, R. J., Nitrogen mustard analogues of choline: potential for use and misuse 55
Colquhoun, D., Biophysicists and biochemists talk about the nAChR 292
Colquhoun, D., Caution: agonists are complex 390
Connell, J. M. C., Focus on Disease: Essential hypertension: rational pharmacotherapy 412
Cook, D. A. and Allen, T. M., Undergraduate education in pharmacology and toxicology 479
Cooper, S. J., Bidirectional effects on behaviour of β-carbolines acting at central benzodiazepine receptors 210
Cooper, S. J., Hernstein's equation: interpreting effects of drugs on behaviour 257
Cossery, J.-M., see Hamon, M.
Costentin, J., see Schwartz, J-C.
Cowan, A. and Gmerek, D. E., *In-vivo* studies on kappa opioid receptors 69
Crabbe, M. J. C., see Cerami, A.
Curry, S. H., Laizure, C. and Devane C. L., Spread-sheet analysis in pharmacokinetic simulations 220
Curzon, G., see Dourish, C. T.
Cutler, S. G., see Bevan, J. A.

D

Dahanukar, S. A., see Thatte, U. M.
de Vlieger, Th. A., see Stoof, J. C.
de Prost, D., Heparin fractions and analogues: a new therapeutic possibility for thrombosis 496
DeFeudis, F. V., New studies on the cerebrovascular endothelium – possible relevance to the interpretation of 'precursor-loading' experiments 51
DeFeudis, F. V. and Moreau, J-P., Studies on somatostatin analogues might lead to new therapies for certain types of cancer 384
Descotes, J., Immunotoxicology: health aspects and regulatory issues 1
Devane, L., see Curry, S. H.
Dickson, R. B. and Lippman, M. E., Role of estrogens in the malignant progression of breast cancer: new perspectives 294
DiPaola, M., see Karlin, A.
Disch, R. L., see Schulman, J. M.
Docherty, J. R. and Hyland, L., Aging and α-adrenoceptor function 131
Dourish, C. T., Hutson, P. H. and Curzon, G., Putative anxiolytics 8-OH-DPAT, buspirone and TVX Q 7821 are agonists at 5-HT_{1A} autoreceptors in the raphé nuclei 212
Dragunow, M., Adenosine: the brain's natural anticonvulsant? 128
Drobník, J., Cisplatin – immunity suppressor or enhancer? 389
Dunne, A., Computers: Pharmacokinetic parameter estimation – some pitfalls 11

E

Ehlert, F. J., 'Inverse agonists', cooperativity and drug action at benzodiazepine receptors 28
El-Fakahany, E. E., see Ramkumar, V.

F

Fagg, G. E., Foster, A. C. and Ganong, A. H., Excitatory amino acid synaptic mechanisms and neurological function 357
Farmer, S. G., Neutrophils and ozone-induced airway hyperreactivity: cause or effect? 169
Finkle, B. S., see Palladino Jr., M. A.
Fisher, J. W., Origins of American pharmacology 41
Fitos, I., see Simonyi, M.
Flavahan, N. A. and Vanhoutte, P.M., α_1-Adrenoceptor subclassification in vascular smooth muscle 347
Foster, A. C., see Fagg, G. E.
Fowler, C. J. The pros and cons of using human brain autopsy samples for radioligand binding experiments 9
Fowler, C. J., The measurement and pharmacological characterization of neurotransmitter function in human autopsy and biopsy samples: the state of the art 85
Francis, K., True random numbers using the random number generator of the microcomputer 124
Frost, J. J., Imaging neuronal biochemistry by emission computed tomography: focus on neuroreceptors 490

G

Galligan, J. J., see Porreca, F.
Ganong, A. H., see Fagg, G. E.
Garbarg, M., see Schwartz, J-C.
García-Sáinz, J. A. and Boyer, J. L., Pertussis toxin and the heart 429
Gmerek, D. E., see Cowan, A.
Godfroid, J. J. and Braquet, P., PAF-acether specific binding sites:1. quantitative SAR study of PAF-acether isosteres 368
Godfroid, J. J., see Braquet, P.
Goldstein, M., Lieberman and Meller, E., The antiparkinson action of bromocriptine in combination with levodopa: Goldstein *et al.* reply 225
Goodman, J. I., Vorce, R. L. and Baranyi-Furlong, B. L., Genetic toxicology: chemical carcinogens modify DNA in a non-random fashion 354
Goudie, A. J. and Griffiths, J. W., Behavioural factors in drug tolerance 192
Gower, A. J., Lesioning of the nucleus basalis in

the rat as a model of Alzheimer's disease 432
Gozlan, H., see Hamon, M.
Grega, G. J., Contractile elements in endothelial cells as potential targets for drug action 452
Griffiths, J. W., see Goudie, A. J.
Grundstrom, N., see Andersson, R. G. G.
Gundlach, A. L., see Manallack, D. T.
Gupta, S., Therapy of AIDS and AIDS-related syndromes 393

H

Habermann, E. and Richardt, G., Intracellular calcium binding proteins as targets for heavy metal ions 298
Håkanson, R., Gastric carcinoids and antisecretory drugs 386
Hamon, M., Cossery, J.-M. Spampinato, U. and Gozlan, H., Are there selective ligands for 5-HT_{1a} and 5-HT_{1b} receptor binding sites in brain? 336
Handley, S. L. and Singh, L., Neurotransmitters and shaking behaviour – more than a 'gut-bath' for the brain? 324
Haynes, L., Inflammation at the home of anaphylaxis 165
Haynes, L. W., Galanin: profile of a new neuropeptide 214
Haynes, L. W., Peptide neuroregulation of vascular tone by the sympathetic nervous system 383
Hedner, T., see Vanhoutte, P. M.
Heikkila, R., see Kindt, M. V.
Hersh, L. B., Nomenclature and classification of enkephalin degrading peptidases 346
Holgate, S. T., see Church, M. K.
Hoult, J. R. S. and Moore, P. K., 6-Keto-prostaglandin E_1: a naturally occurring stable prostacyclin-like mediator of high potency 197
Hoyer, D., Implications of stereoselectivity in radioligand binding studies 227
Hutson, P. H., see Dourish, C. T.
Huxtable, R. J. and Sebring, L. A., Towards a unifying theory for the actions of taurine 481
Hyland, L., see Docherty, J. R.

I

Ingram, E., see Woodcock, B. G.
Inoki, R. and Kudo, T., Enkephalins and bradykinin in dental pulp 275
Izquierdo, I., Vasopressin and ethanol preference 87
Izquierdo, I., Interactions between methylxanthines and benzodiazepine binding sites 256
Izquierdo, I., Memory consolidation: not a useful hypothesis in the search for memory-enhancing drugs 476

J

Jenden, D. J., see Newton, M. W.

K

Kao, P. N., see Karlin, A.
Karlin, A., Kao, P. N. and DiPaolo, M., Molecular pharmacology of the nicotinic acetylcholine receptor 304
Kato, A., Alzheimer's disease from different angles 47
Kebabian, J. W., Agui, T., van Oene, J. C., Shigematsu, K. and Saavedra, J. M., The D_1 dopamine receptor: new perspectives 96
Kenakin, T. P., Receptor reserve as a tissue misnomer 93
Kenny, A. J., see Turner, A. J.
Kindt, M. V., Nicklas, W. J., Sonsalla, P. K. and Heikkila, R., Mitochondria and the neurotoxicity of MPTP 473
Kobilka, B., see Lefkowitz, R. J.
Koelle, G. B., Henry Hallett Dale 1875–1968 288
Koelle, G. B., Otto Loewi 1873–1961 290
Kudo, T., see Inoki, R.

L

Laizure, C., see Curry, S. H.
Lane, R. F., see Phillips, A. G.
Lecomte, J-M., see Schwartz, J-C.
Lefkowitz, R. J., Benovic, J. L., Kobilka, B. and Caron, M. G., β-Adrenergic receptors and rhodopsin: shedding new light on an old subject 444
Lehmann F., P. A., Stereoisomerism and drug action 281
Levitzki, A., Bacterial adaptation, visual adaptation, receptor desensitization – a common link? 3
Lieberman, A., see Goldstein, M.
Lindberg, I., On the evolution of proenkephalin 216
Lindgren, B. R., see Andersson, R. G. G.
Lipnick, R. L., Charles Ernest Overton: Narcosis studies and a contribution to general pharmacology 161
Lippman, M. E., see Dickerson, R. B.
Lodder, J. C., see Stoof, J. C.
Lunde, P. K. M., see Baksaas, I.
Luster, M. I. and Rosenthal, G. J., The immunosuppressive influence of industrial and environmental xenobiotics 408

M

Mackay, D., Towards the classification of receptors 226
Mackay, D., Null equations and agonists: the data fit 437
Madeddu, L., see Meldolesi, J.
Manallack, D. T., Beart, P. M. and Gundlach, A. L., Psychotomimetic σ-opiates and PCP 448
Manara, L., Bianchetti, A. and Roncucci, R., Newer quaternary ammonium opioid antagonists 14
Mandel, H. G., The US Biomedical Research Funding Enterprise 75
Martinez, J. and Potier, P., Peptide hormones as prohormones 139
Mason, S., Chirality Part I: The origin of chirality in nature 20
Matsas, R., see Turner, A. J.
Maulet, Y., see Taylor, P.
Max, B., This and that: please the patient and pass the coffee 12
Max, B., This and that: be still, my fluttering heart 90
Max, B., This and that: of men and science 174
Max, B., This and that: pharmacology and the arts in the year of the peptides 260
Max, B., This and that: agents of change 342
Max, B., This and that: a thistle and some factors 435
McCall, R., see Vanhoutte, P. M.
McGilliard, K. L., A microcomputer program for simulation of quantal dose-response experiments 53
McNeill, J. H. and Tahiliani, A. G., Diabetes-induced cardiac changes 364
Meldolesi, J., Scheer, H., Madeddu, L. and Wanke, E., Mechanism of action of α-latrotoxin: the presynaptic stimulatory toxin of the black widow spider venom 151
Meller, E., see Goldstein, M.
Menke, G., see Woodcock, B. G.
Merritt, J. E., see Taylor, C. W.
Middlemiss, D. N. Functional correlates of the subtypes of the 5-HT_1 recognition site 52
Millar, T. J., see Morgan, I. C.
Moore, P. K. see Hoult, J. R. S.
Moreau, J-P., see Defeudis, F. V.
Morgan, I. G. and Millar, T. J. Ethylene mustard aziridinium ion: a cholinotoxin of the retina *in vivo* 265
Morley, J., Cromoglicate and asthma 132

N

Nahorski, S. R. and Batty, I., Inositol tetrakisphosphate: recent developments in PI metabolism and receptor function 83
Neubert, K., see Brantl, V.
Neumann, H-G., Macromolecules as dose monitors for exposure to environmental chemicals 173
Newton, M. W. and Jenden, D. J., False transmitters as presynaptic probes for cholinergic mechanisms and function 316
Newton, M., see Taylor, P.
Nicklas, W. J., see Kindt, M.V.
Nutt, D., Benzodiazepine dependence in the clinic: reason for anxiety? 457

P

Paalzow, G. H. M. and Paalzow, L. K., L-Dopa: how it may exacerbate parkinsonian symptoms 15
Paalzow, L. K., see Paalzow, G. H. M.
Page, C. P., Adenosine and asthma 265
Palazidou, L., see Stahl, S. M.
Palladino Jr, M. A. and Finkle, B. S., Immunopharmacology of tumor necrosis factors α and β 388
Pang, P. K. T., Yang, M. C. M. and Tenner, Jr, T. E., β-Adrenergic-like actions of parathyroid hormone 340
Patil, P. N., Drug evaluation reports: the junior class project 480
Pearce, F., Reply to Morley
Pearce, F. L., Cromoglicate and asthma: Fred Pearce replies 133
Phillips, A. G., Lane, R. F. and Blaha, C. D., Inhibition of dopamine release by cholecystokinin: relevance to schizophrenia 126
Plempel, M., see Berg, D.
Porreca, F., Galligan, J. J. and Burks, T. F., Central opioid receptor involvement in gastrointestinal motility 104
Potier, P., see Martinez, J.
Pott, L., Electrical aspects of cardiac Na^+–Ca^{2+} exchange 296

R

Rajfer, S. I., see Rossen, J. D.
Ramage, A. G., see Vanhoutte, P. M.
Ramkumar V. and El-Fakahany, E. E., The current status of the dihydropyridine calcium channel antagonist binding sites in the brain 171
Rampe, D. and Triggle, D. J., Benzodiazepines and calcium channel function 461
Rao, M. S., see Reddy, J. K.
Reddy, J. K. and Rao, M. S., Peroxisome profilerators and cancer: mechanisms and implications 438
Regel, E., see Berg, D.
Reidenberg, M. M., Clinical pharmacology and therapeutics: new directions? 381
Reimann, I. H., see Vanhoutte, P. M.
Richardt, G., see Habermann, E.
Richer, C., see Vanhoutte, P. M.
Rietbrock, N., see Woodcock, B. G.
Robertson, H. A. and Robertson, G.S., The antiparkinson action of bromocriptine in combination with levodopa 224
Robertson, G. S., see Robertson, H. A.
Roncucci, R., see Manara, L.
Ronneberger, H.,.Need for additional safety assays for heat-treated plasma protein fractions 130
Rosenthal, G. L., see Luster, M. I.
Ross, S. B., Measurement of intraneuronal monoamine oxidase in the brain 300
Rossen, J. D. and Rajfer, S. I., Oral levodopa in the long-term treatment of heart failure 230
Roth, J. A., Sulfoconjugation: role in neurotransmitter and secretory protein activity 404
Rylett, R. J., see Colhoun, E. H.

S

Saavedra, J. M., see Kebabian, J. W.
Saxena, P. R., see Vanhoutte, P. M.
Saxena, P. R. and Bolt, G. R., Haemodynamic profiles of vasodilators in experimental hypertension 501
Scala, R. A., Toxicology programs and the professionals 478
Schäfer, S. G. and Strugala, G. J., Dietary cadmium and the development of anaemia 430
Schalekamp, M. A. H. D., see Vanhoutte, P. M.
Scheer, H., see Meldolesi, J.
Schmidek, H. H., see Bevan, J. A.
Scholfield, C. N., Adenosine and transmitter release 478

Schulman, J. M. and Disch, R. L., On the recognition of cholinergic agonists by the muscarinic receptor 263
Schumacher, M., see Taylor, P.
Schwartz, J-C., Arrang, J-M. and Garbarg, M., Three classes of histamine receptors in brain 24
Schwartz, J-C., Costentin, J. and Lecomte, J-M., Schwartz *et al.* reply 89
Sebring, L. A., see Huxtable, R. J.
Sever, P. S., 1985 – the year of the hypertension trials; interpreting the results 134
Sharif, N. A., Brain imaging: new approaches to the study of neuronal communication 46
Sherratt, H. S. A., Hypoglycin, the famous toxin of the unripe Jamaican Ackee fruit 186
Shi Jun, see Xu Duan-Zheng
Shigematsu, K., see Kebabian, J. W.
Shih-Fang, F., Pharmacology in China. 179
Silinsky, E. M., Inhibition of transmitter release by adenosine: are Ca^{2+} currents depressed or are the intracellular effects of Ca^{2+} impaired? 180
Simonyi, M., Fitos, I. and Visy, J., Chirality of bioactive agents in protein binding and storage transport processes 112
Singh, L., see Handley, S. L.
Smith, G. E., Can a vaccine prevent cavities? 108
Smith, E. R., see Waud, D. R.
Sonsalla, P. K., see Kindt, M. V.
Spampinato, U., see Hamon, M.
Stahl, S. M. and Palazidou, L., Focus on Disease: The pharmacology of depression: studies of neurotransmitter receptors lead the search for biochemical lesions and new drug therapies 349
Stenberg, K., Cellular methods for measuring drug toxicity *in vitro* 218
Stiles, G. L., Adenosine receptors: structure, function and regulation 486
Stoof, J. C., Werkman, T. R., Lodder, J. C. and de Vlieger, Th., A. Growth hormone producing cells in *Lymnaea stagnalis* as a model system for mammalian dopamine receptors 7
Strange, P. G., Isolation and characterization of D_2 dopamine receptors 253
Stroes, J. W. and Bast, A., Functional receptors and binding sites for tachykinins 302
Strom, B. L., Medical databases in post-marketing drug surveillance 377
Strugala, G. J., see Schafer, S. G.
Struyker-Boudier, H. A. J., see Vanhoutte, P. M.
Symoens, J., see Vanhoutte, P. M.

T

Tahiliani, A. G., see McNeill, J. H.
Talmadge, J. E., Biological response modifiers: realizing their potential in cancer therapeutics 277
Tanz, R. D., The glycosides and their properties 334
Taylor, G. W. and Clarke, S. R., The leukotriene biosynthetic pathway: a target for pharmacological attack 100
Taylor, C. W. and Merritt, J. E., Receptor coupling to polyphosphoinositide turnover: a parallel with the adenylate cyclase system 238
Taylor, P., Schumacher, M., Maulet, Y. and Newton, M. A molecular perspective on the polymorphism of acetylcholinesterase 321
Taylor, C. W., Growth factors control a network of interacting messengers 467
Tenner Jr, T. E., see Pang, P. K. T.
Testa, B., Chiral aspects of drug metabolism 60
Thatte, U. M. and Dahanukar, S. A., Ayurveda and contemporary scientific thought 247
Thiel, G., Nephrotoxicity of ciclosporin 167
Triggle, D. J., see Rampe, D.
Turner, A. J., Kenny, A. J. and Matsas, R. Pharmacology of enkephalinase inhibitors 88
Turner, A. J., Is the Torpedo electric organ a useful system for neuropeptide pharmacology? 215

V

Van Nueten, J. M., see Vanhoutte, P. M.
Van Zwieten, P. A., see Vanhoutte, P. M.
van Oene, J. C., see Kebabian, J. W.
Vanhoutte, P. M., Ball, S. G., Berdeaux, A., Cohen, M. L., Hedner, T., McCall, R., Ramage, A. G., Reimann, I. H., Richer, C., Saxena, P. R., Schalekamp, M. A. H. D., Struyker-Boudier, H. A. J., Symoens, J., Van, Nueten, J. M. and Van Zwieten, P. A., Mechanism of action of ketanserin in hypertension 58
Vanhoutte, P. M., see Flavahan, N. A.
Visy, J., see Simonyi, M.
Vorce, R. L., see Goodman, J. I.

W

Waddington, J. L., Bromocriptine, selective D_2 dopamine receptor agonists and D_1 dopaminergic tone 223
Walle, T. and Walle, U. K., Chirality, Part IV: Pharmacokinetic parameters obtained with racemates 155
Walle, U. K., see Walle, T.
Wanke, E., see Meldolesi, J.
Wann, K. T., Buffering the Good way 55
Waud, D. R. and Smith, E. R., On hearts and automobile engines 391
Webb, D. R., Suppressor factors in immunity 254
Weinstein, H., Molecular models for muscarinic receptors 262
Werkman, T. R., see Stoof, J. C.
Wermuth, C. G. and Bizière, K., Pyridazinyl-GABA derivatives: new class of synthetic GABA antagonists 421
Whittaker, V. P., The storage and release of acetylcholine 312
Woodcook, B. G. and Ingram, E., Digitalis purpurea and the Meddygon Myddvai 178
Woodcock, B. G., Menke, G. and Rietbrock, N., Nitroplasters and bioavailability 338
Woodruff, G. N., Dwindling dopamine receptors 252

X

Xu Duan-Zheng and Shi Jun, Computer analysis of the sequential trial 258

Y

Yang, M.C.M., see Pang, P. K. T.

Subject index

A

Abel, John Jacob 41, 174
Acenocoumarol, stereospecific pharmacokinetics 156
Acetoaminophen, nutrient interactions 35
2-Acetylaminofluorene
  and liver tumors 441
  non-random DNA damage 354
Acetylcholine
  cytoplasmic pools 313
  precursors 51
  and regulatory peptides 215
  storage and release 312
Acetylcholinesterase
  image analysis 46
  polymorphism 321
Acetyl-β-methylcholine, stereoselectivity 203
Acetylsalicylic acid, nutrient interactions 34
Acidic amino acid receptors, classification and properties 358
Acquired immune deficiency syndrome (AIDS) and related syndromes, therapy 393–397
  including antimoniotungstate, AZT, bone marrow transplantation, imunthiol, interferons, isoprinosine, suramin
Adenosine
  as anticonvulsant 128
  and asthma 49, 265
  and Ca^{2+} channels 180
  and metrazole 129
  receptors 486
  and transmitter release 478
Adrenaline, and memory 476
Adrenocorticotropic hormone, and memory 476
α-Adrenergic receptors
  and aging 131
  and asthma (α_2) 177
  desensitization (α_1) 3
  enantiomers (α_1) 202
  and ketanserin (α_1) 58
  and prazosin 132
  in shaking behaviour (α_1/α_2) 325
  subclassification (α_1) 347
  using clonidine, prazosin, yohimbine
β-Adrenergic receptors
  and caffeine 488
  coupling 94
  coupling to adenylate cyclase 238
  desensitization 3
  and levodopa 231
  and hypertension 415
  and kinase 447
  radioligand binding 227
  and rhodopsin 444
  in shaking behaviour 325
  and tricyclic antidepressants 350
β-Adrenergic stimulants, and vascular permeability 454
Aflatoxin B_1, and liver cancer 441
Aging
  and A_1 adenosine receptors 489
  and α-adrenergic receptors 131
Albumin
  as dose monitor (of environmental chemicals) 174
  and drug binding (human serum) 112
  including bilirubin, diazepam, tofisopam, warfarin
Alloxan, and diabetes 364
Alzheimer's disease 47, 320, 432
American pharmacology 41
Amphetamine
  behavioural response, Herrnstein's equation 257
  drug tolerance 195
  stereoselective binding 115
Amrinone, heart failure therapy 381
Amytriptyline, and food intake 33
Anaemia, cadmium-induced 430
Analgesia 166
  and flupirtine 166
Anaphylaxis (Meeting Report) 165
Angiotensin converting-enzyme inhibitors, and essential hypertension 417
Antacids, nutrient interactions 33
Anticonvulsant, adenosine as 128
Anti-estrogens 295
Antifungals 233
Anti-inflammatory drugs (Meeting Report) 165
  and edema 452
Antimoniotungstate (HPA-23), in AIDS therapy 395
Anti-thrombin activity, heparin 496
Anxiety, role of 5-HT 212
Apomorphine, and Parkinson's disease 15
Aromatic hydrocarbons, and immunosuppression 408
Arrhythmogenic currents, in cardiac preparations 297
Asbestos, and immunosuppression 411
Asthma
  and adenosine 49, 265
  and α_2-adrenergic receptors 177
  and cromoglicate 132
  and neutrophils 169
  ozone-induced 169
  and P_1 purinoceptors 50
Atenolol, in antihypertension trials 137
Atrial peptides 435
Autoimmune disease 166
Ayurveda medicine 247
Azoles, antifungal 233
AZT (3'-azido-3'-deoxythymidine), in AIDS therapy 394

B

Bacillus Calmette-Guérin (BCG), in immunotherapy 277
Bacteria, adaptation (Meeting Report) 3
Barbiturates, isomers 202
Bay K 8644, and Ca^{2+} channels 462
Behaviour
  and drug response, Herrnstein's equation 257
  and drug tolerance 192–196
  including amphetamine, morphine, pentobarbital
Behavioural toxicology, experimental approaches 471
Bendrofluazide, antihypertension trials 134
Benzene, and immunosuppression 409
Benzodiazepine receptors 29
  and β-carbolines 210
  central 461
  and clonazepam 507
  and diazepam 506
  and methylxanthines 256
  peripheral 461, 506
  positron emission tomography studies 493
Benzodiazepines
  and Ca^{2+} channels 461
  dependence on 457
Benzomorphans, similarity to phenycyclidine 449
Bestatin, and immunomodulation 280
Bicuculline
  as GABA antagonist 421
  and shaking behaviour 326
Bilirubin, and albumin binding 113
Bioavailability, and nitroplasters 338
Biological response modifiers 277–281
  including BCG, bestatin, interferons, interleukin-2, muramyl dipeptide analogues, tumor necrosis factor, tuftsin
Bombesin
  and β-endorphin 71
  and ethylketazocine 70
  and gastrointestinal transit 104
  receptor and protein kinase C 469
  scratch test 69
Bone marrow transplantation, in AIDS therapy 395
Boston Collaborative Drug Surveillance Program 379
Boston University Drug Epidemiology Unit 379
Bradykinin, and enkephalins in dental pulp 275
Brain
  dihydropyridine-binding sites 171
  human autopsy samples for radioligand binding 9
  imaging (Meeting Report) 46–77
  including acetylcholinesterase, CCK receptors, 2-deoxyglucose utilization, neuropeptide Y
Bromocriptine, and Parkinson's disease (Letters) 223, 224
Bufuralol, enantioselective metabolism 62
BW755C, in leukotriene biosynthesis 102

C

Cadmium, and anaemia 430
Caffeine 12
  and A_1 adenosine receptors 488
Calcitonin gene related peptide (CRGP), and cerebral ischemia 428
Calcium, biochemistry 342
Calcium antagonists, in brain 427
Calcium-binding proteins, and heavy-metal ions 298
Ca^{2+} channels
  and adenosine 180
  and Bay K 8644 171
  and benzodiazepines 461
  and calcium antagonists 172
  and dihydropyridine 461
  voltage-sensitive 171
Calmodulin, and heavy-metal ions 299
Cancer
  biological response modifiers 277

breast, estrogens in 294
and DNA damage 354
gastric, and antisecretory drugs 386
and peroxisome proliferators 438
somatostatin analogues, as therapy 384
and sulfation 407
Captopril, and hypertension 501
Carazolol, stereoselective binding 228
β-Carbolines (Meeting Report) 210–212
including DMCM, Ro15-1788 (flumazepil), ZK 91296, ZK 93423
Carcinogens, chemical, DNA damage 354–357
including 2-acetylaminofluorene, dimethylnitrosamine, methylnitrosourea
Cardiac glycosides 334
Cardiac pharmacology 429
Cardiovascular disease
and diabetes 364
pharmacology 391
Cataracts
and free radicals 273
and glucocorticoids 272
recent advances 271
Catecholamines, sulfonation 405
β-CCE (β-carboline-3-carboxylic acid ethyl ester), and shaking behaviour 326
Central cholinergic function 316
Central opioid receptors 104–107
and enkephalins
and β-funaltrexamine
and gastrointestinal transit
and morphine
Cerebral glucose utilization 426
Cerebral ischemia (Meeting Report) 425
Cerebral vasospasm (Letter) 345
Cerebrovascular endothelium, precursor-loading studies 51
Chen, K. K. 44
Chirality
of bioactive agents 200
classical stereochemistry 20
in clinical pharmacology 381
in drug metabolism 60, 281
in drug–protein interactions 112
and genetics 156
of hybrid drugs 204
origin in nature 20
racemates, pharmacokinetics of 155
radioligand binding studies 227
Chirality of
acenocoumarol 156
acetyl-β-methylcholine 203
α_1-adrenergic receptors 202, 227
amphetamine 115
barbiturates 202
bilirubin 113
bufuralol 62
carazolol 228
chlorpheniramine 114
diazepam 112
hexobarbital 155
ibuprofen 156
indacrinone 202
ketamine 114, 202
labetalol 204
mephenytoin 62, 157
phenoxypropionic acids 203
prilocaine 203
promethazine 114
propranolol 63, 114, 156, 227
selegiline 203
timolol 202
tofisopam 114
verapamil 156
warfarin 113, 155
Chlorpheniramine, stereoselective binding 114
Cholecystokinin (CCK)
active peptides derived from 139
and dopamine release in schizophrenia 126
receptors 46
Cholera toxin, and adenylate cyclase 240
Cholestyramine, nutrient interactions 34
Choline acetyltransferase, and Alzheimer's disease 47, 432
Choline mustard aziridinium ion 55
Choline transport 316
Cholinergic Hypothesis, of memory dysfunction 432
Cholinergic neurons
antibody mapping 47
false transmitters 316
Ciclosporin, nephrotoxicity of 167
Cimetidine
and gastric carcinoids 386
nutrient interactions 33
Cisplatin, and immunity (Letter) 389
Clathrate theory of narcosis 161
Clinical pharmacology (Meeting Report) 381
Clofibrate
and hypoglycin toxicity 191
and peroxisome proliferation 438
Clonazepam, effect on benzodiazepine receptors 507
Clonidine, in subclassification of α_1-adrenergic receptors 347
Clotrimazole 233
Computers
analysis of sequential trials 258
pharmacokinetic parameter estimation 11
quantal dose–response simulation 53
random number generator 124
spread-sheet analysis of pharmacokinetics 220
Conditioned responses, and drug tolerance 194
Contraceptives, herbal 121
Contractile proteins, and vascular permeability 452
Cooperative interactions, between drugs and neurotransmitters 28
Cromoglicate, and asthma 132
Cytochrome P-450, reactive oxygen formation 266

D

DADLE, and opioid receptor function 104
Dale, Henry, H. 288
Dental cavities
and enkephalins in dental pulp 275
and *Streptococcus mutans* 108
vaccines against 108
Dental pulp, enkephalins and bradykinin in 275
2-Deoxyglucose utilization 47
Dependence, on benzodiazepines 457
Depression
and β-adrenergic receptors 350
and 5-HT_2 receptors 350
pharmacology of 349–353
including lithium, mianserin, iprindole, monoamine oxidase inhibitors, rolipram, trazodone, tricyclic antidepressants
Desensitization 3
and adenosine receptors 489
heterologous 447
homologous 446
Dexamethasone, suppression of cortisol secretion 351
Diabetes, and cardiac changes 364
alloxan and streptozocin-induced 364
insulin and vanadate, as therapy 367
Diazepam
and albumin-binding sites 113
and benzodiazepine receptors 506
and shaking behaviour 326
Diethylnitrosamine, and liver tumors 441
Diethylstilbestrol (DES), and immunosuppression 409
Digitalis purpurea, remedies (Letter) 178
Digoxin, and cardiac glycosides 335
Dihydropyridines
binding sites in the brain 171
and Ca^{2+} channels 461
Dimethylnitrosamine, non-random DNA damage 354
DMCM, at benzodiazepine receptors 210
DNA modification, non-random, by chemical carcinogens 354–357
including 2-acetyl aminofluorene, dimethlynitrosamine, methyl-nitrosourea
L-Dopa
and heart failure 230
nutrient interactions 35
and Parkinson's disease 15
Dopamine
and essential hypertension 417
inhibition by cholecystokinin 126
and phenycyclidine 448
sulfonation 405
Dopamine receptors 252
bromocriptine at (D_1/D_2) (Letters) 223, 224, 225
and SCH 23390, SK&F 83566, RU 24213
classification 82
D_1 type 96–99
and fish retina, grooming behaviour, SCH 23390, turning behaviour
D_2 type 253
and RU 24213
and L-dopa in heart failure therapy 232
Lymnaea stagnalis as model system 7
positron emission tomography of 491
Dose monitors
albumin as 174
for environmental chemicals (Current Technique) 173
8-OH-DPAT buspirone, at $5HT_{1A}$ auto-receptors 212
Drug antagonism, in classifying receptors 82
Drug design, functional groups 148
Drug interactions with
neurotransmitters 28
nutrients 33
including acetaminophen, acetyl-salicylic acid, antacids, amytriptyline, cholestyramine, cimetidine, indometacin, isoniazid, levodopa, propranolol
proteins, stereoselectivity 112
receptor 148
Drug metabolism
chiral aspects 60, 281
and sulfoconjugation 404
Drug storage, and stereoselectivity 112
Drug Surveillance Research Unit, UK 379
Drug tolerance, behavioural factors 192–196
including amphetamine, morphine, phenobarbital
Drug toxicity, measurement (Current Technique) 218
Drug transport, and stereoselectivity 112
Drug utilization studies 331
Drugs
anti-inflammatory 165
foscarnet 219
hybrid and pseudo-hybrid 203
local anaesthetic-like 293
post-marketing surveillance 378
vasodilator 501
Dynorphin-A 71

E

ECL cell hyperplasia 387
Edema, and anti-inflammatory agents 452
Education, undergraduate in the USA 208
Efficacy 81, 93
EGF (see Epidermal growth factor)
Endothelial cell stabilizers 452
Eicosanoids 100
and cerebral ischemia 428
5,8,11,14-Eicosatetraynoic acid (ETA), in leukotriene biosynthesis 102
Endopeptidase-24.11 (see Enkephalinase)
β-Endorphin
and bombesin 71
and memory 476
Enkephalinase
inhibitors of 88, 89
in neuropeptide metabolism 216
nomenclature and classification 346
Enkephalins
and bradykinin in dental pulp 275
evolution of 216
and gastrointestinal transit 105
Epidermal growth factor (EGF) 260, 468
and 'anti-cancer' action of SS-14 385
and breast cancer 295
receptor 5, 385
Epilepsy
adenosine therapy 128
and NMDA receptors 363
Estrogens, and breast cancer 294
Ethanol preference, and vasopressin 87

Ethylcholine mustard aziridinium ion 55
and retinal lesions 265
Ethylketazocine, antibombesin effect 70
Excitatory amino acids 357, 425

F
FDGF (see Fibroblast-derived growth factor)
Felodipine, and hypertension 501
Fibrinogen, safety assay after heat-treatment 130
Fibroblast-derived growth factor (FDGF) 468
FLA63, in shaking behaviour 325
Flumazepil (Ro15–1788)
at benzodiazepine receptors 210, 462
and shaking behaviour 326
Flupirtine, in analgesia 166
Flurothyl test, for kappa opioid receptor agonist activity 69
Foscarnet 219
Free radicals
and cataracts 273
and cytochrome P-450 activity 266
and inflammation 165
β-Funaltrexamine, and gastrointestinal transit 105
Functional groups, in drug–receptor interactions 148

G
G proteins 468, 486
GABA
antagonists ($GABA_A$) 421
receptor 29
and shaking behaviour 326
Galanin 214
Gastric carcinoids 386–387
including loxtidine, omeprazole, SK&F 93579
Gastrin 139
Gastrointestinal transit, and opioid receptors 104
Gene expression system, nicotinic acetylcholine receptor 310
Genetics, and stereoselectivity of drugs 156
Glicentin 141
Glucocorticoids
and cataracts 272
and vascular permeability 456
Glyceryl trinitrate, pharmacokinetics 338
Grooming behaviour in rats 98
Growth factors (see individual entries)
and breast cancer 295
26th Harden Conference on 467

H
H_2O_2, microsomal role 266
Halogenated aromatic hydrocarbons 408
Heart failure therapy
amrinone 381
levodopa 230
and milronone 381
Heavy-metal ions, and calcium-binding proteins 298
Heparin
and cerebral ischemia 425
in thrombosis treatment 496
Herbal contraceptives 121
Herrnstein's equation, drug response including D-amphetamine, pentobarbitone, pimozide 257
Hexobarbital
and microsomal H_2O_2 production 268
stereospecific pharmacokinetics 155
Histamine
antagonists (H_2-) 386
receptor (H_1-, H_2-, H_3-) 24
and vascular permeability 452
Homocholine 316
Hormone receptors, classification (Meeting Report) 79
5-HPETE, in leukotriene biosynthesis 102
5-HT
in autopsy and biopsy studies 86
and benzodiazepine withdrawal 460
and cerebral ischemia 427
precursors 51
and shaking behaviour 324
uptake 301
5-HT receptor
and anxiolytics 212
including buspirone, 8-OH-DPAT, TVX Q 7821
classification 82
and hypertension (HT_1) 58
and phosphoinositide metabolism 240
recognition sites
of 5-HT_1 52
of 5-$HT_{1A/1B/1C}$ 336
and SCH 23390 97
and shaking behaviour (5-HT_2) 324
and tricyclic antidepressants (5-HT_2) 350
Human autopsy samples 9, 85
Human biopsy samples 85
Human serum albumin, and drug binding 112
Huntington's chorea 320
Hybrid drugs 203
Hydralazine, and hypertension 501
Hydrochlorthiazide, in antihypertension trials 137
Hypertension
essential, pharmacotherapy 412–417
β-adrenergic receptor antagonist 415
angiotensin converting enzyme inhibitors 417
dopamine antagonists 417
thiazide diuretics 416
haemodynamic profiles 501–506
including captopril, felodipine, hydrolazine, prazosin
and ketanserin 58
mild, treatment trials 134–139
including atenolol, benzofluazide, hydrochlorthiazide, methyldopa, oxprenolol, propranolol, triamterene
Hypoglycin 186
clofibrate as antidote 191

I
Ibontenic acid, and Alzheimer's disease 432
Ibuprofen, stereospecific pharmacokinetics 156
Immunoglobin E receptor 4
Immunomodulation (see Biological response modifiers)
Immunopharmacology 408
Immunosuppression 408–411
including asbestos, benzene, diethylstilbestrol, halogenated aromatic hydrocarbons, organotins, polycyclic aromatic hydrocarbons, *O,O,S*-trimethyl phosphorothioate
Immunotherapy (see Biological response modifiers)
Immunotoxicology 1, 410
Imunthiol, and AIDS 396
In-vitro techniques, in screening drugs 218
Indometacin, nutrient interactions 34
Inflammation, drugs for 452
Inositol tetrakisphosphate 83
Inositol triphosphate, in classifying receptors 81
Insulin
and diabetes 367
receptors 4, 469
Insulin-like growth factors
and breast cancer (IGF-I) 295
receptors 469
Interferons (IFNs)
and AIDS 395
in immunotherapy 277
Interleukins
and AIDS (IL-2) 395
in immunotherapy (IL-2) 277
in inflammatory response 165
Inverse agonists 28
Ion channels
and acidic amino acid receptors 360
in receptor classification 81
using cDNA probes 308
Ionizing radiation, behavioural effects 471
Iron, and anaemia 431
Isoniazid, nutrient interactions 33
Isoprinosine, and AIDS 396
Isoproterenol, compared with parathyroid hormone 340

K
K^+ channel, and phenycyclidine 449
K^+ conductance, adenosine-mediated changes 486
Kainic acid, and Alzheimer's disease 432
Kappa opioid receptors 69–71
bombesin scratch test 69
and dynorphin-A 71
and β-endorphin 71
and ethlyketazocine 70
flurothyl test 69
and ketazocine 69
and MR 2033 71
and tifluadom 69
and U-50488 69
Ketamine
isomers 202
stereoselective binding 114
Ketanserin, in hypertension 58
Ketazocine 69

L
Labetalol, chirality and activity 204
Lactation, and A_1 adenosine receptors 489
α-Latrotoxin 151
Leake, Chauncey 45
Learning
and NMDA receptors 359
tests with toxicants 472
Leukotrienes 381
B_4 100
biosynthesis 100–103
including BW755C, 5,8,11,14-eicosatetraynoic acid, 5-HPTE, lipocortin, phospholipase A_2, piriprost, salazosulfapyridine
C_4 100
LTC_4 receptor 477
Lipocortin, in leukotriene biosynthesis 102
Lithium
as antidepressant 352
in characterizing receptors 83
Local anaesthetic-like drugs 293
Loewi, Otto 43, 290
Loxtidine, and gastric carcinoids 386
LTC_4 receptor 477
Lymnaea stagnalis, dopamine receptors in 7

M
Mast cell activation, and cromoglicate 132
Medicaid 380
Memory 320
and adrenocorticotropic hormone 476
consolidation hypothesis 476
dysfunction, Cholinergic Hypothesis 432
and β-endorphin 476
and NMDA receptors 359
Mephenytoin, chirality 62, 157
MERF ([Met]enkephalin–Arg–Phe), evolution of 216
MERGL ([Met]enkephalin–Arg–Gly–Leu), evolution of 216
Methyldopa, in antihypertension trials 137
Methylnitrosourea, and non-random DNA damage 354
Methylxanthines, interaction with benzodiazepine-binding sites 256
Metrazole (pentrazole), and adenosine 129
Mianserin iprindole, as antidepressant 352
Miconazole 233
Milrinone, in heart failure therapy 381
Monoamine oxidase
inhibitors, and depression 349
measurement in brain (Current Technique) 300
positron emission tomography studies 494
Morphine
and gastrointestinal transit 105
in shaking behaviour 324
tolerance 194
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
and mitochondria 473
neurotoxic agent 426
and Parkinson's disease 473, 492
positron emission tomography studies 492
MR 2033 71

Muramyl dipeptide analogs, and immunomodulation 280
Muscarinic receptors
and Alzheimer's disease 48
and cholinergic agonists 263
molecular models 262
and pertussis toxin 429
and phosphoinositide metabolism 84, 239
positron emission tomography studies 495
Muscimol, and shaking behaviour 326

N
Na^+/Ca^+ exchange
and cardiac glycosides 334
electrical aspects 296
Na^+/H^+ antiporter
and growth factors 468
and hypoxic brain damage 427
Na^+/K^+-transporting ATPase 334
and diabetes 365
Nafenopin 440
Narcosis, clathrate theory of 161
Narcotic antagonists, quaternary ammonium opioid 4
Narcotics 163
Neurokinin-binding site, classification (Letter) 437
Neuromedin K, binding site 65
Neuromuscular junction
acetylcholinesterase in 321
α-latrotoxin receptors at 153
Neuropeptidase Y 46
Neuropeptide pharmacology, *Torpedo* as model system 215
Neurotransmission
and adenosine 181
and Ca^{2+} channels 181
modulation mechanism 28
and shaking behaviour 324
sulfoconjugation and 404
Neutrophils, and ozone-induced asthma 169
Nicotinic acetylcholine receptor
desensitization 4
cDNA probes 308
functional sites 304
structure 292
Nifedipine 172
Nitrogen mustard, analogues of choline 55
Nitroplasters, and bioavailability 338
NMDA (*N*-methyl-D-aspartate) receptors
and neurological function 357
and phenycyclidine 449
Noradrenaline
in autopsy/biopsy studies 86
and benzodiazepine withdrawal 460
uptake system 301

O
Omeprazole, and gastric carcinoids 386
On/off effects 17
Oncogenes
and carcinogens 354
rcs 468
Opiate receptors, positron emission tomography studies 492
Opioid peptides
biological activity 142
in dental pulp 276
in food proteins 6
metabolism of 215
Opioid receptors
central, in gastrointestinal transit 104
kappa 69
Organotins, and immunosuppression 411
Ouabain, and cardiac glycosides 335
Overton, Charles, E. 161
Oxprenolol, in antihypertension trials 136
Ozone-induced asthma 169

P
pA_2
antagonist–receptor binding 79, 226
value for prazosin 347
value for yohimbine 347
PAF-acether specific binding sites 368, 397
Parathyroid hormone (PTH), compared with isoproterenol 340
Pargyline, and mitochondrial respiration 475
Parkinson's disease
and apomorphine 15
bromocriptine therapy 223, 224, 225
levodopa therapy 15, 51
and MPTP 473
positron emission tomography studies 492
Parvalbumin, and heavy-metal ions 299
Passive avoidance response 320
PDGF (see Platelet-derived growth factor)
Pentobarbital, drug tolerance 195
Pentobarbitone, behavioural response, Herrnstein's equation 257
Peroxisome proliferators, and cancer including clofibrate, nafenopin, plasticizers 438–443
Pertussis toxin
and heart 429
and phospholipase C 240
Pharmacokinetics
of apomorphine 16
data analysis 11
and drug design 148
of glyceryl trinitrate 338
of racemates 155
spread-sheet analysis 220–223
phenytoin
procainamide
Pharmacology
American 41
cardiac 429
clinical 381
of depression 349
history 41
neuropeptide 215
teaching 391, 478, 479
Phenoxypropionic acids, stereoselectivity 203
Phenylcyclidine (Angel dust)
and cerebral ischemia 425
recognition site 448
R-Phenylisopropyladenosine, and A_1 adenosine receptor 486
Phenytoin, computer simulation of pharmacokinetics 221
Phosphatidylcholine, and taurine 482
Phosphatidylethanolamine, and taurine 482
Phosphoinositide, and growth factors 468
Phosphoinositidase C, and growth factors 468
Phospholipase A_2, in leukotriene biosynthesis 102
Phospholipase C, coupling with receptors 239
Pimozide, behavioural response, Herrnstein's equation 257
Piripost, in leukotriene biosynthesis 103
Placebo effect 13, 381
Plasma protein–drug interaction, stereoselectivity 112
Plasma protein fractions, safety assays after heat treatment 130
Plasticizers, and peroxisome proliferation 438
Platelet-activating factor, effect of cromoglicate on late-onset response to 132
Platelet-derived growth factor (PDGF) 468
and breast cancer 295
Platelets, human
and heparin 499
receptor function in depressed patients 351
Polycyclic aromatic hydrocarbons, and immunosuppression 411
Polyphosphoinositide metabolism, and receptor coupling 238
Positron emission tomography (PET)
of brain glucose metabolism 426
of neuroreceptors 490
Post-mortem studies, of depressed patients 351
Prazosin
and α-adrenergic receptors 132
in hypertension 501
in subclassification of α_1-adrenergic receptors 347
Prilocaine, stereoselectivity 203
Procainamide, computer simulation of pharmacokinetics 221
Proenkephalin, evolution 216
Prohormones 139
including cholecystokinin, gastrin, opioid peptides, substance P, tuftsin
Promethazine, stereoselective binding 114
Propranolol
in antihypertension trials 134
enantioselective metabolism 63
nutrient interactions 35
pharmacokinetics of racemates 156
radioligand binding 227
stereoselective binding 114
and stress 91
Prostaglandins 381
6-keto-prostaglandin E_1 197
and vascular permeability 453
Proteins
atrial peptides 435
calcium binding 298
contractile and drug action 452
drug interaction 112
excitatory amino acids 357
G-proteins 468, 486
and hormone action 139
neuropeptides 215
opioid peptides in food 6
tyrosine kinases 469
vasoactive intestinal polypeptide 48
Proteoglycans, heparin 496
Purinoceptors (P_1), and asthma 50
Pyridazinyl-GABA derivatives 421

Q
Quantal dose–response, microcomputer programme 53
Quantitative Structure Activity Relations (QSAR) 281
study of PAF-acether isosteres 368
Quantitative Stereo-Structure Activity Relations (QSSAR) 281
Quaternary ammonium opioid antagonists 14
Quinolinic acid, and Alzheimer's disease 432
Quisqualate/kainate receptors 357

R
Racemates (see Chirality)
Radioactive microsphere technique, for haemodynamic profiles 501
Radioligand binding
using human autopsy samples 9
and stereoselectivity 227
Random number generator, microcomputer 124
Ranitidine, and gastric carcinoids 386
rcs oncogene 468
Reactive oxygen, formed by cytochrome P-450 266
Receptors
abnormalities in depressed patients 349
binding studies 491
classification 79, 82, 226, 390, 437
desensitization 3
drug interactions 148
lithium in characterizing 83
pA_2 measurement 79
and polyphosphoinositide turnover 238
purification 253
reserve 93
spare 93
Torpedo neuronal 292
in xenobiotics 440
Receptors (see individual entries)
Renal toxicity, and ciclosporin 168
Research funding, US 75
Retina
dopamine receptors in (fish)
ethylcholine mustard aziridinium ion lesions 265
Rheumatic disease 166
Rhodopsin
and β-adrenergic receptor 444
and kinase 447
Ro5-4864, and benzodiazepine receptors 508
Ro15-1788 (see Flumazepil)
Rolipram, depression therapy 353
RU 24213 (dopamine D_2 receptor agonist) 223

S
Salazosulfapyridine, in leukotriene biosynthesis 102
SCH 23390 (dopamine receptor antagonist) 96, 223, 224, 225

Schild plots, receptor classification (Letter) 82, 437
Schizophrenia, and dopamine release 126
Seizures, and adenosine 128
Selegiline
  isomers 203
  and mitochondrial respiration 475
Sequential trials, computer analysis of 258
Shaking behaviour 324
  and adrenergic receptors (α/β), bicuculline, β-CCE, diazepam, FLA63, GABA, 5-HT, morphine, muscimol, Ro 15-1788, Tropin-releasing hormone (TRH)
Silymarin, remedies 435
Site-directed mutagenesis, and nAChR 311
SK&F 83566
  dopamine and D_1 receptor 223
  induced grooming behaviour in rats 98
  and 5-HT receptor 97
SK&F 93579, and gastric carcinoids 386
SK&F 10047, recognition sites 448
Smoke, toxic behavioural effects 471
Soluble immune response suppressor (SIRS) 254
Somatostatin analogues, in cancer therapy 384
Stereochemistry (see Chirality)
Streptococcus mutans, in dental decay, vaccine against 108
Streptokinase, and cerebral ischemia 425
Streptozotocin, and diabetes 364
Substance K, binding site 65
Substance P
  binding site 65
  biological activity 146
  and cerebral ischemia 428
Suppressor factors, in immunity 254
Suramin, in AIDS therapy 395

T

Tachykinin receptors 65
Tardive dyskinesia 320
Taurine
  and membrane function 481
  and phosphatidylcholine 482
  and phosphatidylethanolamine 482
Teaching
  pharmacology 391, 478, 479
  toxicology 478, 479
Terbutaline, and vascular permeability 454
TGFs (see Transforming growth factors)
Theophylline, and A_1 adenosine receptors 489
Thiazide diuretics, and essential hypertension 416
Threshold limit values for toxic chemicals 173
Thromoboxane 381
Thymic hormones, and AIDS 395
Thyroid hormones
  and A_1 adenosine receptors 489
  and diabetes 366
Tifluadom 69
Timolol, isomers 202
Tissue plasminogen activator, and cerebral ischemia 425
Tofisopam, stereoselective binding 113
Torpedo
  as model system for neuropeptide pharmacology 215
  neuronal receptor 292
Toxicity
  of ciclosporin 167
  of clofibrate 191
  dose monitors 173
  of drugs, measurement 218
  of ionizing radiation 471
  of MPTP 426
  of pertussis toxin 240, 429
  renal 168
  of smoke 471
Toxicology, behavioural 471
Transduction mechanisms 444
Transforming growth factors (TGFs) 260
  and breast cancer (α/β) 294
Transmembrane signalling 444
  and adenosine receptors 486
Transmitter release, and adenosine 478
Trazodone, as antidepressant 352
Triamterene, antihypertension trials 137
Tricyclic antidepressants (TCAs) 349
O,O,S-Trimethyl phosphorothioate, and immunosuppression 409
Tropin-releasing hormone (TRH) receptors 84
  and phosphoinositide metabolism 468
  and shaking behaviour 324
Tuftsin
  biological activity 146
  and immunomodulation 280
Tumor necrosis factor (TNF)
  immunopharmacology of (α/β) 388
  in immunotherapy 277
Turning behaviour, induced by dopaminergic agonists 98
TVX Q 7831, at 5-HT_{1A} autoreceptors 212
Tyrosine-specific protein kinase, and growth factors 468

U

U-50488 69
Ultrasonic calls, rat behaviour in response to toxicants 472
Unconditioned responses, drug tolerance 194
Urogastrone 260

V

Vaccines, against dental cavities 108
Vanadate, and diabetes 367
Vascular permeability, anti-inflammatory agents 452–457
  including glucocorticoids, histamine, prostaglandins
Vasoactive intestinal polypeptide
  and acetylcholine 215
  and Alzheimer's disease 48
Vasodilator drugs, haemodynamic profiles 501
Vasopressin 467
  and ethanol preference 87
  and memory 476
Verapamil
  in brain, effect on binding sites and calcium uptake 172
  stereospecific pharmacokinetics 156
Visual adaptation 3

W

Warfarin
  labelling albumin-binding sites 113
  stereospecific pharmacokinetics 155

Y

Yohimbine
  in subclassification of α_1-adrenergic receptors 347
  and benzodiazepine withdrawal 460

Z

ZK 93423 and ZK 91296, at benzodiazepine receptors 210